Patrys Limited · ASX:PAB
Patrys — Investor Presentation (September 2014)
24 slides from Patrys's investor presentation, Sep 18, 2014
Slide 1: Investor Presentation
For personal use only Investor Presentation Dr. Marie Roskrow, CEO & Managing Director September 2014 ASX: PAB
Slide 2: Safe Harbour Statement
Safe Harbour Statement For personal use only This presentation contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of Patrys Limited to be materially different
Slide 3: Highlights of 2014
Highlights of 2014 For personal use only 3rd Quarter (July – September): o Released details of the planned PAT-SM6 & carfilzomib Phase Ib/IIa clinical trial due to start end of 2014 o Reported significant progress on all preclinical programmes o Progressed the GMP manufacturing of PAT-SM6 2nd Quarte
Slide 4: Corporate Overview
Corporate Overview For personal use only KEY STATS & FINANCIALS – 17 SEPT. 2014 (AUD$) MANAGEMENT & BOARD ASX Code PAB Marie Roskrow, BSc Managing Director, CEO Share price $0.021 (Hons), MBBS, PhD 52 week high $0.092 Roger McPherson, CFO, Company Secretary CPA, GAICD 52 week low $0.021 Frank Hensel
Slide 5: Pipeline
Pipeline For personal use only Product Discovery Preclinical Phase I Phase 2a (Target) Phase I PAT-SM6 Melanoma Completed (GRP78) PAT-SM6 Phase I/IIa Multiple Myeloma Single Agent Completed 2013 (GRP78) PAT-SM6 Phase Ib/IIa Multiple Myeloma Combination Carfilzomib (GRP78) Commence 2014 PAT-LM1 Solid
Slide 6: PAT-SM6
For personal use only PAT-SM6
Slide 7: Patrys' Lead Antibody: PAT-SM6
Patrys’ Lead Antibody: PAT-SM6 For personal use only PAT-SM6: o IgM isotype, λ-light chain o Isolated from stomach cancer patient o Targets tumour specific epitope on GRP78 o Binds also to oxidised LDL and VLDL Mode of Action: o Internalisation upon binding of oxidised LDL & GRP78PAT-SM6 o Internali
Slide 8: Multiple Myeloma - Opportunity
Multiple MultipleMyeloma Myeloma- Opportunity – Opportunity For personal use only o Cancer of the plasma cells in bone marrow. Cells grow out of control and form tumours in solid bone, cause damage to other organs o Estimated to be more than 220,000 cases worldwide and incidence increasing o 5 year
Slide 9: Multiple Myeloma - Pathology
Multiple Myeloma – Pathology For personal use only o Abnormal plasma cells (myeloma o Abnormal proteins in serum detected cells) secrete lots of “useless” by electrophoresis antibodies (M proteins) o Myeloma cells crowd out other blood cells resulting in anaemia, thrombocytopenia (bleeding) and leuc
Slide 10: Multiple Myeloma - Clinical Presentation
Multiple Myeloma – Clinical Presentation For personal use only o Bone disease and hypercalcaemia o Abnormal protein deposits o Bone marrow failure and infections 10
Slide 11: Therapies for Multiple Myeloma
Therapies for Multiple Myeloma For personal use only Proteosome inhibitors Stem cell transplantation o Bortezomib (Velcade) o Autologous o Carfilzomib (Kyprolis) o Allogeneic Clinical studies Immunomodulators (IMIDs) o Small molecules o Lanalidomide (Revlimid) o Antibodies, peptides o Pomalyst (Poma
Slide 12: Antibodies in Clinical Trials for MM
Antibodies in Clinical Trials for MM For personal use only MOR 202 PAT-SM6* (MorphoSys/Celgene, Phase I/IIa) (Patrys, Phase Ib/IIa) Daratumumab (Genmab/Janssen Biotech,Phase III) Elotuzumab (BSM/Abbott, Phase III) GRP78 BHQ880 (Novartis, Phase II) CD138 toxin- conjugated (BT062, Biotest AG, Phase I/
Slide 13: PAT-SM6 Monotherapy Trial
PAT-SM6 Monotherapy Trial For personal use only o 12 patients treated with 4 doses PAT-SM6 in 4 dose cohorts (0.3mg/kg, 1mg/kg, 3mg/kg and 6mg/kg/dose) evaluated at day +36 (end of trial) • 10 male, 2 female: median age 71 yrs • Received average 5 prior lines of therapy o PAT-SM6 safe in all patient
Slide 14: Clinical Data: Preliminary Efficacy
Clinical Data For personal use only Preliminary Efficacy M Protein Changes from Baseline (%) 140% 120% 114% 100% Stable Stable Stable Stable 81% 80% disease disease disease disease Increase/Decrease 60% 54% 48% 42% 40% 36.30% 40% 20% 13% 7% 1.40% 1% 0% 01-001 01-002 01-003 02-001 02-002 02-003 03-00
Slide 15: Clinical Data
Clinical Data anti Isotype Control For personal use only CD138 PAT-SM6 Immunohistochemical staining with PAT- PAT-SM6 SM6 on paraffin embedded tumour Isotype biopsies from MM patients Control The positive control (anti-CD138) and PAT- SM6 bound to patient tissues Flow cytometry on MM patient bone ma
Slide 16: PAT-SM6 & Carfilzomib Combination Trial
PAT-SM6 & Carfilzomib Combination Trial Endpoints: For personal use only o Primary: The safety and tolerability of PAT-SM6, given in combination with carfilzomib and dexamethasone in patients with multiple myeloma who are refractory and/or intolerant to bortezomib, a currently-marketed proteasome in
Slide 17: Cell Lines Used in Manufacturing Antibodies
Cell Lines Used in Manufacturing Antibodies For personal use only PER.C6® Cell Line: o Patrys uses PER.C6® human cell line for GMP production: Only human cell line commercially available Over 6300 patients have been treated with PER.C6® products – safe profile PER.C6® cell line has received re
Slide 18: PAT-LM1
For personal use only PAT-LM1
Slide 19: PAT-LM1 Antibody & Target
PAT-LM1 Antibody & Target PAT-LM1: For personal use only o IgM isotype, λ-light chain o Isolated from a lung cancer patient o Targets tumour-specific epitope of surface- expressed NONO (non-POU-domain-containing octomer binding protein) Mode of Action: o NONO mainly found in nucleus: involved in tra
Slide 20: PAT-LM1 Preclinical Data
PAT-LM1 Preclinical Data + control - control PAT-LM1 0.4 For personal use only without C1q coating Lung Squamous Cell Carcinoma 0.35 with 5μ/ml C1q coating 0.3 Colon 0.25 Adenocarcinoma 0.2 OD655 0.15 Esophagus Squamous Cell Carcinoma 0.1 0.05 Breast Ductal Adenocarcinoma 0 20μg 10μg 5μg 1μg 0.5μg L
Slide 21: PAT-SC1
For personal use only PAT-SC1
Slide 22: PAT-SC1 (Gastric Cancer)
PAT-SC1 (Gastric Cancer) PAT-SC1: For personal use only o Pentameric IgM isotype, λ-light chain o Isolated from a stomach cancer patient o Targets isoform of CD55 (Decay Accelerating Factor) expressed on surface of multiple types of cancer cells POC Trial Results: o Phase I/IIa (POC) open-label tria
Slide 23: 2014 Key Milestones
2014 Key Milestones For personal use only Projected Timing Key Milestone (CY) PAT-SM6: o Final data from monotherapy MM trial 1Q, 2014 o Complete GMP manufacturing for combination MM trial 2H, 2014 o Commence combination Phase Ib/IIa MM trial 4Q, 2014 o Preclinical and clinical data published 4Q,
Slide 24: For Further Information
For personal use only For Further Information Contact Details: Dr. Marie Roskrow, Chief Executive Officer / Managing Director Mr. Roger McPherson, Chief Financial Officer Ph: +61 3 9670 3273 Email: info@patrys.com Website: www.patrys.com